Earnings ·
Talphera, Inc. reported financial results for the second quarter ended June 30, 2026, posting a net loss of $4.3…
TLPHTalphera, Inc.
Talphera, Inc. reported financial results for the second quarter ended June 30, 2026, posting a net loss of $4.3 million, or $0.06 per share, compared to a $3.5 million loss in the prior year period. Combined R&D and SG&A expenses totaled $3.9 million, driven by higher Niyad development costs as enrollment increased. The company holds $17.1 million in cash and investments. Clinically, the NEPHRO CRRT study for nafamostat is 75% enrolled with site realignment complete, targeting year-end completion. Updated KDIGO guidelines now list nafamostat as an acceptable anticoagulant, and revised market research estimates 200,000 annual U.S. CRRT procedures in 2027, a 21% increase over previous projections. Talphera is a specialty pharmaceutical company focused on developing innovative therapies for medically supervised settings.